Zeliras HOPE SPV Secures US$681,000 Fourth Funding Tranche
Filed with ASX · · 2 pages · English
Zelira Therapeutics Ltd. on 6ix
Story so far
Earlier from Zelira Therapeutics
- September 2024 Quarterly Activities Report
- Appendix 4C Cash Flow Report
- Appendix 4E and Financial Report to Shareholders
- June 2024 Quarterly Activities Report
- ZLD Advances HOPE Autism Drug Program with U.S FDA Meeting
Later from Zelira Therapeutics
- Zelira receives $1,153,000 R&D Tax Incentive Scheme Refund
- Appendix 4D & FY25 Interim Financial Report
- Zelira secures $1 Million At-the-Market Funding Facility
- Publication of ZLT-L-007 IRB Approved Observational Study
- Zelira Therapeutics Secures R&D Loan Facility
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics